Aliases & Classifications for Mucositis

MalaCards integrated aliases for Mucositis:

Name: Mucositis 12 52 42 14
Inflammatory Disease of Mucous Membrane 69
Gastrointestinal Mucositis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0080178
MeSH 42 D052016

Summaries for Mucositis

Disease Ontology : 12 A gastrointestinal system disease that is characterized by painful inflammation and ulceration of the mucous membranes lining the digestive tract.

MalaCards based summary : Mucositis, also known as inflammatory disease of mucous membrane, is related to bernard-soulier syndrome, type c and malaria, and has symptoms including oral manifestations, signs and symptoms, digestive and catarrh. An important gene associated with Mucositis is CSF2 (Colony Stimulating Factor 2), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Sucralfate and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and bone, and related phenotypes are growth/size/body region and behavior/neurological

Wikipedia : 72 Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract,... more...

Related Diseases for Mucositis

Diseases related to Mucositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 600)
id Related Disease Score Top Affiliating Genes
1 bernard-soulier syndrome, type c 29.8 ABCB1 CSF2 IL2 MTOR VEGFA
2 malaria 28.2 CSF2 CSF3 IL2 TYMS VEGFA
3 hemolytic anemia 27.6 ABCB1 CSF2 CSF3 IL2 MTOR VEGFA
4 lung cancer 26.1 ABCB1 CSF2 CSF3 EGF MTOR TYMS
5 colorectal cancer 25.9 ABCB1 CSF2 DPYD EGF IL2 MTHFR
6 mucosal melanoma 12.2
7 venous malformations, multiple cutaneous and mucosal 12.1
8 multiple mucosal neuroma 11.9
9 multiple endocrine neoplasia iib 11.5
10 cicatricial pemphigoid 11.5
11 ocular cicatricial pemphigoid 11.4
12 white sponge nevus 1 11.2
13 gastritis 11.1
14 mallory-weiss syndrome 11.1
15 allergic rhinitis 10.9
16 oral candidiasis 10.9
17 eosinophilic gastroenteritis 10.9
18 granular cell tumor 10.9
19 pemphigus foliaceus 10.9
20 epidermolysis bullosa 10.9
21 gastritis, familial giant hypertrophic 10.9
22 intestinal tuberculosis 10.9
23 hemophilia a 10.9
24 chronic mucocutaneous candidiasis 10.9
25 lassa fever 10.9
26 white sponge nevus of cannon, krt4-related 10.7
27 white sponge nevus of cannon, krt13-related 10.7
28 squamous cell carcinoma, head and neck 10.7
29 factor x deficiency 10.7
30 dyskeratosis congenita, autosomal dominant 3 10.7
31 dyskeratosis congenita, autosomal recessive 5 10.7
32 autoinflammatory syndrome, familial, behcet-like 10.7
33 plasminogen deficiency, type i 10.7
34 lymphoma, malt, somatic 10.7
35 bleeding disorder, platelet-type, 8 10.7
36 schimmelpenning-feuerstein-mims syndrome, somatic mosaic 10.7
37 mastoiditis 10.7
38 dyskeratosis congenita, autosomal dominant 2 10.7
39 primary systemic mycosis 10.6 CSF2 CSF3
40 angiosarcoma 10.6 CSF3 VEGFA
41 inflammatory bowel disease 14 10.6
42 epidermolysis bullosa, junctional, non-herlitz type 10.6
43 factor vii deficiency 10.6
44 inflammatory diarrhea 10.6
45 inflammatory bowel disease 19 10.6
46 duodenal atresia 10.6
47 dyskeratosis congenita, autosomal recessive 2 10.6
48 dyskeratosis congenita, autosomal recessive 1 10.6
49 inflammatory bowel disease 25, early onset, autosomal recessive 10.6
50 hypersensitivity syndrome, carbamazepine-induced 10.6

Graphical network of the top 20 diseases related to Mucositis:



Diseases related to Mucositis

Symptoms & Phenotypes for Mucositis

UMLS symptoms related to Mucositis:


oral manifestations, signs and symptoms, digestive, catarrh

MGI Mouse Phenotypes related to Mucositis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.21 MTOR RSPO1 TGFB3 VEGFA XRCC1 ABCB1
2 behavior/neurological MP:0005386 10.18 ABCB1 CSF2 FGF7 HTR3A IL2 MTOR
3 homeostasis/metabolism MP:0005376 10.14 VEGFA XRCC1 ABCB1 CSF2 FGF7 HTR3A
4 immune system MP:0005387 10.07 TGFB3 VEGFA ABCB1 CSF2 CSF3 EGF
5 endocrine/exocrine gland MP:0005379 10.06 ABCB1 CSF2 EGF HTR3A IL2 MTOR
6 integument MP:0010771 9.97 CSF2 CSF3 EGF FGF20 FGF7 HTR3A
7 nervous system MP:0003631 9.96 ABCB1 CSF2 FGF20 FGF7 HTR3A MTHFR
8 renal/urinary system MP:0005367 9.63 CSF2 CSF3 FGF7 HTR3A MTOR VEGFA
9 reproductive system MP:0005389 9.61 ABCB1 CSF2 EGF FGF7 HTR3A IL2
10 skeleton MP:0005390 9.23 CSF2 DPYD FGF7 MTHFR MTOR RSPO1

Drugs & Therapeutics for Mucositis

Drugs for Mucositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 489)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sucralfate Approved Phase 4,Phase 3 54182-58-0
2
Cetuximab Approved Phase 4,Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
3
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-21-8 3385
4
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
5
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
7
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
8
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
9
Metronidazole Approved Phase 4 443-48-1 4173
10
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2 55-56-1 9552079 2713
11
Ethanol Approved Phase 4,Phase 1 64-17-5 702
12
Hexetidine Approved Phase 4 141-94-6
13
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
14
Budesonide Approved Phase 4 51333-22-3 63006 5281004
15
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
16
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
17
Amifostine Approved, Investigational Phase 4,Phase 2 20537-88-6 2141
18
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 1400-61-9 11953884
19
Cilastatin Approved Phase 4 82009-34-5 5280454 6435415
20
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
21
Meropenem Approved, Investigational Phase 4 119478-56-7 64778 441130
22
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
23
Norethindrone Approved Phase 4 68-22-4 6230
24
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-81-7 5785 54670067
25
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Early Phase 1 114977-28-5 148124 9877265
26
Camptothecin Experimental Phase 4,Phase 2 7689-03-4
27 Antacids Phase 4,Phase 3,Phase 2
28 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
29 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
33 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Mitomycins Phase 4
37 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
38 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
39 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antiparasitic Agents Phase 4,Phase 2
42 Antiprotozoal Agents Phase 4,Phase 2
43 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
46 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 449)

id Name Status NCT ID Phase Drugs
1 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
2 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
3 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
4 Oral Zinc Therapy for the Prevention of Mucositis Completed NCT00449592 Phase 4 Zinc;Placebo
5 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
6 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
7 Non Surgical Treatment of Periimplantitis Completed NCT02023853 Phase 4 metronidazole gel
8 Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash;Placebo
9 INEC Study: Immuno-modulating Enteral Nutrition in Cancer Completed NCT00333099 Phase 4
10 Tolerability, Efficacy and Mucosal Inflammation Associated With Orally Administered Colon Cleansing for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
11 Hexetidine and Chlorobutanol for Lesions Due to Prostheses Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
12 Mouth Care Regimes During Radiotherapy Completed NCT00138827 Phase 4 Biotene (mouth care)
13 Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients Completed NCT00204958 Phase 4 nutritional supplement;glutamine popsicle
14 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
15 The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device Completed NCT02079792 Phase 4
16 Allergic Rhinitis Changes the Sinus Microbiome Completed NCT01852513 Phase 4 QNASL;Placebo nasal spray
17 The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma Completed NCT01305369 Phase 4 Prasugrel
18 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
19 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
20 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Recruiting NCT01876407 Phase 4
21 Impact of Oral Hygiene Gels on Peri-implant Mucositis Recruiting NCT03243591 Phase 4
22 Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer Recruiting NCT01707641 Phase 4
23 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
24 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
25 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO Recruiting NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
26 Effect of Probiotic Lactobacillus Reuteri in the Treatment of Mucositis and Periimplantitis Active, not recruiting NCT03047291 Phase 4 Probiotic
27 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Active, not recruiting NCT01200355 Phase 4 micafungin;posaconazole
28 Oral Hygiene Regimen in Patients on HCT Enrolling by invitation NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
29 The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Not yet recruiting NCT02905890 Phase 4 Norethisterone enantate
30 Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
31 Low-energy Laser Therapy for Prevention of Oral Mucositis in Children Unknown status NCT01007617 Phase 2, Phase 3
32 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
33 Lactobacillus Brevis CD2 Preventing Oral Mucositis Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
34 Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation Unknown status NCT02313792 Phase 3 Palifermin
35 Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults Unknown status NCT02173756 Phase 3 morphine gel;placebo gel
36 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
37 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
38 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
39 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
40 Omalizumab in Non-atopic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
41 COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma Unknown status NCT00603759 Phase 3 celecoxib;placebo
42 Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia Unknown status NCT01598402 Phase 2, Phase 3 amoxicillin/clavulanic acid suspension
43 Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis Completed NCT00814359 Phase 3 Combination of Magic Mouthwash Plus Sucralfate;0.15% Benzydamine HCl
44 Curcumin for Prevention of Oral Mucositis in Children Chemotherapy Completed NCT00475683 Phase 3
45 Prevention Chemotherapy Induced Mucositis by Zinc Sulfate Completed NCT01015183 Phase 2, Phase 3 Zinc Sulfate;Placebo
46 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer Completed NCT00615420 Phase 3
47 Low-level Laser Therapy on Inflammatory Mediators During Chemotherapy-induced Oral Mucositis Completed NCT02050373 Phase 3
48 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
49 To Access the Effects of Mucositis in Adults With Dental Implants Completed NCT01072201 Phase 3 Triclosan and Fluoride;Fluoride
50 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Completed NCT00101582 Phase 3 Placebo;palifermin;cisplatin chemotherapy

Search NIH Clinical Center for Mucositis

Cochrane evidence based reviews: mucositis

Genetic Tests for Mucositis

Anatomical Context for Mucositis

MalaCards organs/tissues related to Mucositis:

39
Colon, T Cells, Bone, Bone Marrow, Skin, Myeloid, Small Intestine

Publications for Mucositis

Articles related to Mucositis:

(show top 50) (show all 2496)
id Title Authors Year
1
The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of Bordetella pertussis. ( 28928960 )
2017
2
Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. ( 28926601 )
2017
3
Efficacy of Traditional Chinese Medicine in Treatment and Prophylaxis of Radiation-Induced Oral Mucositis in Patients Receiving Radiotherapy: A Randomized Controlled Trial. ( 28870095 )
2017
4
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. ( 28092667 )
2017
5
Honey Mitigates Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients without Affecting the Tumor Response. ( 28878156 )
2017
6
Sinonasal mucosal melanoma: A 44-case study and literature analysis. ( 28442409 )
2017
7
Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin. ( 28071062 )
2017
8
Arytenoid neuromas are a recognized feature of SOS1 mutations causing pure mucosal neuroma syndrome. ( 28863001 )
2017
9
Autoimmune progesterone dermatitis manifesting as mucosal erythema multiforme in the setting of HIV infection. ( 28050592 )
2017
10
Antimicrobial photodynamic therapy on treatment of infected radiation-induced oral mucositis: Report of two cases. ( 28826732 )
2017
11
Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in mice. ( 28860040 )
2017
12
Sphenoid sinus mucosal thickening in the acute phase of pituitary apoplexy. ( 28421421 )
2017
13
Oral mucosal epithelial cells express the membrane anchored mucin MUC1. ( 27810385 )
2017
14
Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats. ( 28848081 )
2017
15
Genetic variants alter T-bet binding and gene expression in mucosal inflammatory disease. ( 28187197 )
2017
16
Hypoxia inducible factor-1I+-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease. ( 27921309 )
2017
17
Biochemical, hematological, and pathological related healing effects of Elaeagnus angustifolia hydroalcoholic extract in 5-fluorouracil-induced oral mucositis in male golden hamster. ( 28895047 )
2017
18
Endoscopic Mucosal Resection is Superior to Rectal Suction Biopsy for Analysis of Enteric Ganglia in Constipation and Dysmotility. ( 28893560 )
2017
19
Loss of immune control in HIV-infected patients: how does mucosal candidiasis occur? ( 27922753 )
2017
20
Distinct peripheral vs mucosal T-cell phenotypes in chlamydia-infected women. ( 28949051 )
2017
21
Endoscopic resection of sinonasal mucosal melanoma has comparable outcomes to open approaches. ( 28490408 )
2017
22
Laugier-Hunziker syndrome: a case of asymptomatic mucosal and acral hyperpigmentation. ( 28515989 )
2017
23
BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. ( 28485171 )
2017
24
Randomized control trial of benzydamine HCl versus sodium bicarbonate for prophylaxis of concurrent chemoradiation-induced oral mucositis. ( 28942587 )
2017
25
Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. ( 28078646 )
2017
26
TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients. ( 28403570 )
2017
27
Small bowel dilation in children with short bowel syndrome is associated with mucosal damage, bowel-derived bloodstream infections, and hepatic injury. ( 28689603 )
2017
28
Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). ( 28332989 )
2017
29
Extraosseous Calcification of the Esophagus: Clinicopathologic Correlates of Esophageal Mucosal Calcinosis. ( 28932755 )
2017
30
Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab. ( 28497158 )
2017
31
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. ( 28056206 )
2017
32
Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib. ( 28868012 )
2017
33
Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab. ( 28443313 )
2017
34
The Effect of Oral Care Using an Oral Health Care Guide on Preventing Mucositis in Pediatric Intensive Care. ( 28888518 )
2017
35
Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease. ( 27993536 )
2017
36
Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis. ( 28797456 )
2017
37
Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide. ( 28081677 )
2017
38
The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients. ( 28791814 )
2017
39
Mycoplasma pneumoniae-induced rash and mucositis: a recently described entity. ( 28830900 )
2017
40
Loss of nuclear BAP1 expression is associated with poor prognosis in oral mucosal melanoma. ( 28404968 )
2017
41
Double-blind placebo-controlled randomized clinical trial evaluating doxycycline effects on chemotherapy-induced oralA mucositis. ( 28948645 )
2017
42
Systemic and mucosal pre-administration of recombinant Helicobacter pylori neutrophil-activating protein prevents ovalbumin-induced allergic asthma in mice. ( 28087613 )
2017
43
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. ( 27792058 )
2017
44
Utility of esophageal mucosal impedance as a diagnostic test for esophageal disease. ( 28437259 )
2017
45
Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. ( 28600969 )
2017
46
H. pylori infection increases gastric mucosal COX2 and mTOR expression in chronic gastritis: Implications for cancer progression? ( 28668512 )
2017
47
Clinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men. ( 28534034 )
2017
48
Spectrum of small-bowel mucosal abnormalities identified by capsule endoscopy in patients with portal hypertension of varied etiology. ( 28066855 )
2017
49
Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients. ( 28072717 )
2017
50
Cutaneous and Mucosal Manifestations of SjAPgren's Syndrome. ( 28871434 )
2017

Variations for Mucositis

Expression for Mucositis

Search GEO for disease gene expression data for Mucositis.

Pathways for Mucositis

Pathways related to Mucositis according to GeneCards Suite gene sharing:

(show all 28)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 CSF2 CSF3 EGF FGF20 FGF7 IL11
2
Show member pathways
13.56 CSF2 CSF3 EGF IL11 IL2 MTOR
3
Show member pathways
13.45 EGF FGF20 FGF7 IL11 IL2 MTOR
4
Show member pathways
13.21 CSF2 CSF3 EGF FGF20 FGF7 IL11
5
Show member pathways
13.16 EGF FGF20 FGF7 IL2 TGFB3 VEGFA
6
Show member pathways
13.14 CSF2 CSF3 EGF FGF20 FGF7 IL11
7
Show member pathways
13.12 CSF2 CSF3 EGF FGF20 FGF7 IL11
8
Show member pathways
12.96 EGF FGF20 FGF7 IL2 MTOR TGFB3
9
Show member pathways
12.94 EGF FGF20 FGF7 IL2 MTOR TGFB3
10
Show member pathways
12.59 EGF FGF20 FGF7 IL2 TGFB3
11 12.51 EGF FGF20 FGF7 MTOR TGFB3 VEGFA
12 12.48 CSF3 EGF FGF20 FGF7 IL2 MTOR
13
Show member pathways
12.42 CSF2 EGF FGF20 FGF7 MTOR TGFB3
14
Show member pathways
12.3 EGF FGF20 FGF7 VEGFA
15 11.96 EGF FGF7 IL11 VEGFA
16
Show member pathways
11.89 CSF2 CSF3 IL11 IL2 MTOR
17 11.88 CSF2 CSF3 IL11 IL2
18 11.8 EGF MTOR VEGFA
19 11.79 CSF2 CSF3 IL11
20 11.71 CSF2 IL11 TGFB3 VEGFA
21 11.64 EGF FGF20 FGF7 IL2 TGFB3
22 11.6 EGF IL2 MTOR
23
Show member pathways
11.57 CSF2 IL2 VEGFA
24
Show member pathways
11.34 CSF2 IL2 TGFB3
25 11.26 CSF2 CSF3 EGF FGF7
26 11 CSF2 CSF3 IL11 IL2 TGFB3
27 10.94 EGF IL11 TGFB3 VEGFA
28 10.4 CSF2 CSF3 IL11 IL2

GO Terms for Mucositis

Cellular components related to Mucositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 CSF2 CSF3 EGF FGF20 FGF7 IL11
2 platelet alpha granule lumen GO:0031093 9.13 EGF TGFB3 VEGFA

Biological processes related to Mucositis according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.92 ABCB1 MTHFR TYMS XRCC1
2 platelet degranulation GO:0002576 9.8 EGF TGFB3 VEGFA
3 response to hypoxia GO:0001666 9.78 MTHFR TGFB3 VEGFA XRCC1
4 phosphatidylinositol phosphorylation GO:0046854 9.77 EGF FGF20 FGF7
5 peptidyl-tyrosine phosphorylation GO:0018108 9.76 CSF2 EGF FGF20 FGF7
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 CSF3 IL11 VEGFA
7 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.72 EGF FGF20 FGF7
8 positive regulation of protein phosphorylation GO:0001934 9.71 IL2 MTOR RSPO1 VEGFA
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 CSF2 IL2 VEGFA
10 cell growth GO:0016049 9.67 MTOR TGFB3 TYMS
11 response to ethanol GO:0045471 9.62 CSF3 HTR3A IL2 TYMS
12 mammary gland alveolus development GO:0060749 9.61 EGF VEGFA
13 monocyte differentiation GO:0030224 9.61 CSF2 VEGFA
14 positive regulation of cell division GO:0051781 9.61 FGF7 TGFB3 VEGFA
15 growth GO:0040007 9.58 MTOR VEGFA
16 tetrahydrofolate interconversion GO:0035999 9.58 MTHFR TYMS
17 tetrahydrofolate metabolic process GO:0046653 9.57 MTHFR TYMS
18 phosphatidylinositol-mediated signaling GO:0048015 9.56 EGF FGF20 FGF7 MTOR
19 positive regulation of cell proliferation GO:0008284 9.56 CSF2 CSF3 EGF FGF20 FGF7 IL11
20 MAPK cascade GO:0000165 9.55 CSF2 EGF FGF20 FGF7 IL2
21 response to folic acid GO:0051593 9.54 MTHFR TYMS
22 positive regulation of keratinocyte migration GO:0051549 9.52 FGF7 MTOR
23 macrophage differentiation GO:0030225 9.32 VEGFA
24 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.1 CSF3 EGF FGF7 IL11 MTOR VEGFA
25 neutrophil differentiation GO:0030223 9.07 CSF2
26 positive regulation of GTPase activity GO:0043547 10 CSF2 EGF FGF20 FGF7 IL2

Molecular functions related to Mucositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.56 CSF2 EGF FGF20 FGF7
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.55 CSF2 EGF FGF20 FGF7 IL2
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGF FGF20 FGF7
4 cytokine activity GO:0005125 9.43 CSF2 CSF3 IL11 IL2 TGFB3 VEGFA
5 growth factor activity GO:0008083 9.28 CSF2 CSF3 EGF FGF20 FGF7 IL11

Sources for Mucositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....